Table of contents


On 9 July 2001, orphan designation (EU/3/01/044) was granted by the European Commission to Aventis Behring GmbH, Germany, for human alpha-1-proteinase inhibitor (respiratory use) for the treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency.

The sponsor changed name to ZLB Behring GmbH in February 2005 and subsequently to CSL Behring GmbH in April 2007.

Key facts

Active substance
Human alpha1-proteinase inhibitor
Disease / condition
Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency
Date of decision
Orphan decision number

Sponsor's contact details

CSL Behring GmbH
Emil-von-Behring-Str. 76
35041 Marburg
Tel. + 49 6421 3912

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating